

S-Metolachlor/Sulfentrazone

**S-Metolachlor/Sulfentrazone EC (A23479A) -
Acute Oral Toxicity Study in Rats
(Up and Down Procedure)**

Final Report

TEST GUIDELINE(S): OECD 425 (2008)
EPA 870.1100 (2002)

AUTHOR(S): Nikoletta Szalóki, Ph.D

COMPLETION DATE: 29 June 2021

PERFORMING LABORATORY: Charles River Laboratories Hungary Kft.
H-8200 Veszprém, Szabadságpuszta, hrsz. 028/1.,
Hungary

LABORATORY PROJECT ID: Report Number: 21/032-001P
Study Number: 21/032-001P
Task Number: TK0521994

SPONSOR(S): Syngenta Ltd.
Jealott's Hill International Research Centre
Bracknell, Berkshire, RG42 6EY, United Kingdom

STATEMENT OF DATA CONFIDENTIALITY CLAIMS

The Following Statement Applies To The United States of America:

STATEMENT OF NO DATA CONFIDENTIALITY CLAIMS UNDER SPECIFIED FIFRA PROVISIONS

No claim of confidentiality, on any basis whatsoever, is made for any information contained in this document. I acknowledge that information not designated as within the scope of FIFRA sec. 10(d)(1)(A), (B), or (C) and which pertains to a registered or previously registered pesticide is not entitled to confidential treatment and may be released to the public, subject to the provisions regarding disclosure to multinational entities under FIFRA 10(g).

Company: Syngenta Crop Protection, LLC
410 Swing Road
Post Office Box 18300
Greensboro, NC 27419-8300 USA

Submitter: _____ Date: _____

Syngenta is the owner of this information and data. Syngenta has submitted this material to the United States Environmental Protection Agency specifically under the provisions contained in FIFRA as amended and, hereby, consents to use and disclosure of this material by EPA according to FIFRA. In submitting this material to EPA according to method and format requirements contained in PR Notice 2011-3, we do not waive any protection or right involving this material that would have been claimed by the company if this material had not been submitted to the EPA, nor do we waive any protection or right provided under FIFRA Section 3 (concerning data exclusivity and data compensation) or FIFRA Section 10(g) (prohibiting disclosure to foreign and multinational pesticide companies or their agents).

GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT

This study has been performed in accordance with the Principles of Good Laboratory Practice (Hungarian GLP Regulations: 42/2014. (VIII. 19.) EMMI decree of the Ministry of Human Capacities which corresponds to the OECD GLP, ENV/MC/CHEM (98) 17.).

This study was conducted in accordance with a written Study Plan, authorized by the Sponsor and Charles River Laboratories Hungary Kft. Management, and followed applicable Standard Operating Procedures.

No chemical analysis of the dose formulation was performed as part of this study. Traceability (equipment used, quantities of test item weighed) of dosing form preparations was checked and revealed no abnormalities of consequence. Furthermore, for this study, the formulations were prepared just before the treatment. Consequently, the absence of dose formulation analysis data was considered not to prejudice the overall GLP status of the study and the scientific reliability of the study conclusions.

I, the undersigned, declare that this report constitutes a true record of the actions undertaken and the results obtained in the course of this study. By virtue of my dated signature I accept the responsibility for the validity of the data.

Signature: Nikoletta Szalóki
Nikoletta Szalóki, Ph.D
Study Director

Date: 29 June 2021

Performing Laboratory: Charles River Laboratories Hungary Kft.
H-8200 Veszprém, Szabadságpuszta, hrsz. 028/1.,
Hungary

To be completed for USA EPA submission only:
Representative of Submitter/Sponsor:

_____ Date

Submitter/Sponsor: Syngenta Crop Protection, LLC
410 Swing Road
Post Office Box 18300
Greensboro, NC 27419-8300 USA

FLAGGING STATEMENT

This page is intentionally left blank. It will be replaced by an appropriate Flagging statement by the sponsor.

QUALITY ASSURANCE STATEMENT

Study Number: 21/032-001P


Study Title: S-metolachlor/sulfentrazone EC (A23479A) - Acute Oral Toxicity Study in Rats (Up and Down Procedure)

Test Item: S-metolachlor/sulfentrazone EC (A23479A)

This study has been inspected, and this report audited by the Quality Assurance Unit in compliance with the Principles of Good Laboratory Practice. As far as it can be reasonably established the methods described and the results incorporated in this report accurately reflect the raw data produced during this study.

All inspections, data reviews and the report audit were reported in written form to the Study Director and to Management. The dates of such inspections and of the report audit are given below:

Date of Inspection	Phase(s) Inspected/Audited	Date of report to	
		Management	Study Director
06 April 2021	Study Plan	06 April 2021	06 April 2021
13 April 2021	Treatment	13 April 2021	13 April 2021
26 May 2021	Amendment 1 to the Study Plan	26 May 2021	26 May 2021
24 June 2021	Draft Report	24 June 2021	24 June 2021
29 June 2021	Final Report	29 June 2021	29 June 2021

Signature: 
Eszter Sebestyén, B.Sc.
On behalf of QA

Date: 29 June 2021

MANAGEMENT STATEMENT

According to the conditions of the research and development agreement between Syngenta Ltd. (as Sponsor) and Charles River Laboratories Hungary Kft. (as Test Facility) the study titled "S-metolachlor/sulfentrazone EC (A23479A) - Acute Oral Toxicity Study in Rats (Up and Down Procedure)" has been performed in compliance with the Principles of Good Laboratory Practice.

Signature: Balász Tóth Date: 29 June 2021
Balázs Tóth, Ph.D.
General Manager

GENERAL INFORMATION

Contributors

The following contributed to this report in the capacities indicated:

Name	Function or Department
Nikoletta Szalóki, Ph.D. (Reporting)	Study Director
Erika Rosos-Matting, M.Sc. (In Life Phase)	Study Director
Csilla Gyömöreiné Nagy, Ph.D.	Assistant Scientist
Eszter Sebestyén, B.Sc.	Quality Assurance
László Székelyhidi, D.V.M.	Veterinary Care
Tamás Mészáros, Ph.D.	Pharmacy
Ferenc Szűcs	Animal Service Laboratories
Carolina Vaccari	Syngenta Study Manager

Other trained, competent personnel worked on the study as required.

Study dates

Study Initiation Date	06 April 2021
Experimental Starting Date	13 April 2021
Experimental Completion Date	11 May 2021
Draft Report	25 June 2021
Final Report	29 June 2021
Receipt of Animals	08 April 2021

Treatment	13 April 2021 (female no. 9486)
	15 April 2021 (female no. 9487)
	20 April 2021 (female no. 9488)
	22 April 2021 (female no. 9489)
	27 April 2021 (female no. 9490)

Observation	13 April – 27 April 2021 (female no. 9486)
	15 April – 29 April 2021 (female no. 9487)
	20 April – 04 May 2021 (female no. 9488)
	22 April – 06 May 2021 (female no. 9489)
	27 April – 11 May 2021 (female no. 9490)

Necropsy	27 April 2021 (female no. 9486)
	29 April 2021 (female no. 9487)
	04 May 2021 (female no. 9488)
	06 May 2021 (female no. 9489)
	11 May 2021 (female no. 9490)

Deviation from the Study Plan

Due to technical reason, relative humidity values (up to 78%) outside the expected range of 30-70% were recorded on some occasions during the study. This deviation has no effect on the outcome of the study.

Performing laboratory test substance reference number

200480

Other

The study documents and samples:

- Study Plan and its amendment
- all raw data,
- sample of the test item,
- original Study Report and any amendments,
- correspondence

will be archived according to the Hungarian GLP regulations and to applicable SOPs in the archives of Charles River Laboratories Hungary Kft. H-8200 Veszprém, Szabadságpuszta, hrsz. 028/1., Hungary.

After the retention time of 15 years has elapsed all the archived materials listed above will be returned to the Sponsor or retained for a further period if agreed by a contract. Otherwise the materials will be discarded.

TABLE OF CONTENTS

STATEMENT OF DATA CONFIDENTIALITY CLAIMS	2
GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT	3
FLAGGING STATEMENT	4
QUALITY ASSURANCE STATEMENT	5
MANAGEMENT STATEMENT	6
GENERAL INFORMATION	7
TABLE OF CONTENTS	9
1.0 EXECUTIVE SUMMARY	11
1.1 Study Design	11
1.2 Results	11
1.3 Conclusion.....	11
2.0 INTRODUCTION	12
2.1 Purpose.....	12
2.2 Guidelines	12
2.3 Test Facility.....	12
3.0 MATERIALS AND METHODS	12
3.1 Test Substance.....	12
3.1.1 Identification and receipt.....	13
3.1.2 Formulation	13
3.2 Experimental Design.....	13
3.2.1 Animals	13
3.2.2 Husbandry	13
3.2.3 Food and feeding.....	14
3.2.4 Water supply and quality control	14
3.3 Administration of the Test Item	14
3.3.1 Dosages	14
3.3.2 Procedure.....	15
3.4 Observations.....	15
3.4.1 Clinical observations	15
3.4.2 Body weight measurement.....	15
3.5 <i>Post Mortem</i> Investigations.....	16
3.5.1 Material used for euthanasia	16

3.6	Data Evaluation	16
4.0	RESULTS AND DISCUSSION	17
4.1	Mortality	17
4.2	Clinical Signs	17
4.3	Body Weights	17
4.4	Macroscopic Findings	17
5.0	CONCLUSIONS	17
	TABLES SECTION	18
TABLE 1	Individual Findings – Clinical Signs	19
TABLE 2	Body Weight and Body Weight Gain	20
TABLE 3	Macroscopic Findings	21
	APPENDICES SECTION	22
APPENDIX 1	AOT 425 Report (Limit Test)	23
APPENDIX 2	Certificate of Analysis	24
APPENDIX 3	Structured Study Summary	25
APPENDIX 4	GLP Certificate	26

1.0 EXECUTIVE SUMMARY

1.1 Study Design

In this acute oral toxicity (up and down procedure) study, 5 female Crl:WI rats were given a single oral (gavage) dose of S-metolachlor/sulfentrazone EC (A23479A) at dose level of 2000 mg/kg body weight (bw).

Individual animals were dosed sequentially at no less than 48-hour intervals. The time intervals between doses were determined by the onset, duration and severity of clinical signs. The first animal was treated at a dose level of 2000 mg/kg bw. The dose selection for the next animals followed the recommendation of AOT425StatPgm software, based on available results.

Animals were observed individually at 30 minutes, and 1, 2, 3, 4 and 6 hours post treatment and once each day for 14 days thereafter. Body weight was measured on Day -1 (prior to removal of food), before dosing (on Day 0), on Day 7 and on Day 14. All animals were euthanized and examined macroscopically at the end of the observation period.

1.2 Results

No mortality was observed at the dose level of 2000 mg/kg bw during the study.

Slightly decreased activity was observed in 4/5 animals on Day 0. Hunched back was observed on Day 0 (2/5), until Day 1 (2/5) or Day 2 (1/5). From Day 3 all the animals were symptom-free.

There was no test item related effect on body weight or body weight gain in any animals. Body weights were within the range commonly recorded for this strain and age.

A single oral gavage of S-metolachlor/sulfentrazone EC (A23479A) to Crl:WI female rats dosed at 2000 mg/kg bw with a 14 day of observation period was not associated with any macroscopic changes.

1.3 Conclusion

Under the conditions of this study, the acute oral median lethal dose (LD₅₀) of the test item S-metolachlor/sulfentrazone EC (A23479A) was found to be greater than 2000 mg/kg bw in female Crl:WI Wistar rats.

2.0 INTRODUCTION

2.1 Purpose

The purpose of the study was to assess the acute oral toxicity of the test item S-metolachlor/sulfentrazone EC (A23479A) when administered as a single oral gavage dose to female rats at one or more defined dose levels.

This study was performed with vertebrate animals as no *in vitro* alternative is available. The study was designed such that the minimum numbers of animals were used.

2.2 Guidelines

The study was performed according to the following guidelines:

- OECD Guidelines Reference 425 (2008): Acute Oral Toxicity - Up-and-Down Procedure.
- United States Environmental Protection Agency, Health Effects Test Guidelines, OPPTS 870.1100 Acute Oral Toxicity EPA 712-C-02-190, December 2002.

2.3 Test Facility

This study was performed in an AAALAC-accredited laboratory. The Institutional Animal Care and Use Committee (IACUC) of Charles River Laboratories Hungary Kft. reviewed the Study Plan and authorized the conduct of the study.

3.0 MATERIALS AND METHODS

3.1 Test Substance

The following information was provided by the Sponsor:

Name:	S-metolachlor/sulfentrazone EC (A23479A)
Product code:	A23479A
Batch number:	RAN001-086-038
Active ingredient content*:	Content of S-metolachlor: 75.30 % w/w corresponding to 848.13 g/L, content of sulfentrazone: 7.71 % w/w corresponding to 86.87 g/L
Density:	1.1264 g/cm ³
Appearance:	Amber liquid
Recertification date:	01 May 2022
Storage conditions:	Room temperature (<30°C)
Safety precautions:	Routine safety precautions (gloves, goggles, face mask, lab coat) were applied considering the supplied safety datasheet to assure personnel health and safety.

**Note: No adjustment for active ingredient content was applied.*

The Certificate of Analysis is presented in Appendix 2.

3.1.1 Identification and receipt

The test item of a suitable active ingredient content together with all precautions required in the handling and disposal of the test item were supplied by the Sponsor. The identification of the test item was made in the Pharmacy of Charles River Laboratories Hungary Kft. on the basis of the information provided by the Sponsor.

3.1.2 Formulation

The test item was administered undiluted and used as supplied by the Sponsor.

3.2 Experimental Design

3.2.1 Animals

Species and strain:	CrI:WI Wistar rats
Source:	Charles River Laboratories, Research Models and Services, Germany GmbH, Sandhofer Weg 7, D-97633 Sulzfeld, Germany
Hygienic level:	SPF at arrival, standard housing conditions during study
Justification of strain:	Recognized by international guidelines as a recommended test system.
Number of animals:	5 (1 animal/step)
Sex:	Female rats, nulliparous and non-pregnant
Age when treated:	Young adult rats, 8 weeks old
Body weight (at dosing):	198 – 236 g
Identification:	The animals were identified by numbers written on the tail with an indelible pen. The cages were marked with individual identity cards with information about study number, sex, cage number, dose group and individual animal number.
Randomization:	Selected by hand at time of delivery
Acclimatisation time:	At least 5 days

3.2.2 Husbandry

Animal health:	Only healthy animals were used for the test. The health status was certified by the Veterinarian.
Housing / Enrichment:	Animals were housed individually in Type II. polypropylene/polycarbonate cages. Rodents were housed with deep wood sawdust bedding to allow digging and other normal rodent activities. Additional

	enrichment (hiding tunnels) were also used during the study.
Bedding / Nesting:	SAFE 3/4 S certified wooden chips and SAFE crinklets natural nest building material produced by J. Rettenmaier & Söhne GmbH + CO.KG (D-73494 Rosenberg, Germany) were available to animals during the study. Copies of the Certificate of Analysis are retained in the Archive at Charles River Laboratories Hungary Kft.
Light:	12 hours daily, from 6.00 a.m. to 6.00 p.m.
Temperature:	19.3-24.3°C
Relative humidity:	34-78%
Ventilation:	15-20 air exchanges/hour

The temperature and relative humidity were recorded twice daily during the acclimatisation period and throughout the study.

3.2.3 Food and feeding

Animals received ssniff SM R/M "Autoclavable complete diet for rats and mice – breeding and maintenance" (Batch no.: 713 70882 / 18776795, Expiry date: 30 April 2021 / 31 August 2021) produced by ssniff Spezialdiäten GmbH, D-59494 Soest, Germany *ad libitum*. The food was considered not to contain any contaminants that could reasonably be expected to affect the purpose or integrity of the study. Details of the diets are archived with the raw data at Charles River Laboratories Hungary Kft.

3.2.4 Water supply and quality control

Animals received tap water from the municipal supply from 500 mL bottles *ad libitum*. The water was fit for human consumption and was considered not to contain any contaminants that could reasonably be expected to affect the purpose or integrity of the study.

Water quality control analysis is performed once every three months and microbiological assessment is performed monthly by Veszprém County Institute of State Public Health and Medical Officer Service (H-8200 Veszprém, József Attila utca 36, Hungary). The quality control results are retained in the archive at Charles River Laboratories Hungary Kft.

3.3 Administration of the Test Item

3.3.1 Dosages

Justification of the doses:

The starting dose of the limit test was 2000 mg/kg bw after discussion with the Sponsor.

The animals were treated with a single oral (gavage) dose of S-metolachlor/sulfentrazone EC (A23479A) at the dose level of 2000 mg/kg bw. The dose volume was 1.78 mL/kg bw. The individual dose volumes used are shown below.

Animal Number	Dose [mg/kg body weight]	Volume Dosed [mL]	Bodyweight [g]	Mortality
9486	2000	0.42	236	Survived
9487	2000	0.35	198	Survived
9488	2000	0.37	210	Survived
9489	2000	0.38	211	Survived
9490	2000	0.39	219	Survived

Rationale:

Oral administration was considered to be an appropriate dose route as it is a possible route of human exposure.

3.3.2 Procedure

A single oral (gavage) dose was followed by a 14-day observation period. The animals were fasted overnight prior to treatment. Water was still available, *ad libitum* overnight. Animals were weighed before dosing and the food was returned 3 hours after the treatment.

Individual animals were dosed sequentially following an interval of at least 48 hours. The time intervals between doses were determined by the onset, duration and severity of toxic signs.

3.4 Observations

3.4.1 Clinical observations

Animals were observed individually at 30 minutes, 1, 2, 3, 4 and 6 hours after dosing, then once each day for 14 days. Individual observations were performed on the skin, fur, eyes, mucous membranes, somatomotor activity and behaviour pattern as well as respiratory, circulatory, autonomic and central nervous systems.

Particular attention was directed to observation of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma.

3.4.2 Body weight measurement

The body weights were recorded on Day -1 (prior to removal of food), on Day 0 (before dosing), on Day 7 and on Day 14 (before necropsy) in all animals until termination.

3.5 *Post Mortem* Investigations

All animals were subjected to gross macroscopic evaluation. All surviving animals were euthanised under pentobarbital anaesthesia (Euthanimal 40%, details in section 3.5.1) at the end of the observation period. After examination of the external appearance, the cranial, thoracic and abdominal cavities were opened then the appearance of the tissues and organs were observed. All gross pathological changes were recorded for each animal on the post mortem record sheets and the animals were discarded.

3.5.1 Material used for euthanasia

Name: Euthanimal 40% (sodium pentobarbital)
Lot No.: 2001004-06
Expiry Date: 31 January 2023
Produced by: Alfasan Nederland BV, Kuipersweg 9, Woerden,
The Netherlands

3.6 Data Evaluation

Type, severity and duration of clinical observations are described in the tables and results of this report. Body weight and body weight changes are summarised in tabular form. Necropsy findings are described and summarised in tabular form.

Data were recorded on the appropriate forms from the relevant SOPs of Charles River Laboratories Hungary Kft., and then tabulated using the Microsoft Office Word and/or Excel or collected using the software PROVANTIS v.9.

The LD₅₀ was calculated using the AOT425StatPgm program. This program was prepared for the US Environmental Protection Agency by Westat, May 2001 and updated by the US EPA June 2003. This program was constructed using the most appropriate method to estimate the LD₅₀.

4.0 RESULTS AND DISCUSSION

4.1 Mortality

No mortality was observed at the dose level of 2000 mg/kg bw during the study.

4.2 Clinical Signs

Slightly decreased activity was observed in 4/5 animals on Day 0. Hunched back was observed on Day 0 (2/5), until Day 1 (2/5) or Day 2 (1/5). From Day 3 all animals were symptom-free.

Individual clinical observations and mortality results are presented in Table 1.

4.3 Body Weights

There was no test item related effects on body weight or body weight gain in any animal during the study. Body weights were within the range commonly recorded for this strain and age.

Individual body weights are presented in Table 2.

4.4 Macroscopic Findings

A single oral gavage of S-metolachlor/sulfentrazone EC (A23479A) to Crl:WI female rats dosed at 2000 mg/kg bw with a 14 day of observation period was not associated with any macroscopic changes.

Macroscopic findings are presented in Table 3.

5.0 CONCLUSIONS

Under the conditions of this study, the acute oral median lethal dose (LD₅₀) of the test item S-metolachlor/sulfentrazone EC (A23479A), was found to be greater than 2000 mg/kg bw in female Crl:WI Wistar rats.

TABLES SECTION

TABLE 1 Individual Findings – Clinical Signs

DOSE LEVEL: 2000 mg/kg bw, Treatment on Day 0

SEX: FEMALE

Cage No.	Animal Number	Observations	Observation days													Frequency
			0						1	2	3	4	5	6	7-14	
			30'	1h	2h	3h	4h	6h								
1	9486	Symptom Free	-	-	-	-	-	-	-	+	+	+	+	+	+	13/20
		Activity decreased	Sl	Sl	Sl	Sl	Sl	Sl	-	-	-	-	-	-	-	6/20
		Hunched back	+	+	+	+	+	+	+	-	-	-	-	-	-	7/20
2	9487	Symptom Free	-	-	-	-	-	-	-	-	+	+	+	+	+	12/20
		Activity decreased	Sl	Sl	Sl	Sl	Sl	Sl	-	-	-	-	-	-	-	6/20
		Hunched back	+	+	+	+	+	+	+	+	-	-	-	-	-	8/20
3	9488	Symptom Free	-	-	-	-	-	-	+	+	+	+	+	+	+	14/20
		Activity decreased	Sl	Sl	Sl	Sl	Sl	-	-	-	-	-	-	-	-	5/20
		Hunched back	+	+	+	+	+	+	-	-	-	-	-	-	-	6/20
4	9489	Symptom Free	-	-	-	-	-	-	+	+	+	+	+	+	+	14/20
		Activity decreased	-	-	-	Sl	Sl	-	-	-	-	-	-	-	-	2/20
		Hunched back	+	+	+	+	+	+	-	-	-	-	-	-	-	6/20
5	9490	Symptom Free	+	-	-	-	-	-	-	+	+	+	+	+	+	14/20
		Hunched back	-	+	+	+	+	+	+	-	-	-	-	-	-	6/20

Standard

footnotes:

+ = present

- = absent

h = hour (s)

' = minute

= Found dead

M = Moribund

Frequency of observation = number of occurrence of observation / total number of observations

Severities:

Sl = Slight/Small/Few/Small amount

Mo = Moderate/Several/Moderate amount

Ex = Severe/Large/Many/Large/Extreme amount

TABLE 2 Body Weight and Body Weight Gain

DOSE LEVEL: 2000 mg/kg bw, Treatment on Day 0 **SEX: FEMALE**

Cage No.	Animal Number	Body weight (g)				Body Weight Gain (g)		
		Days				0-7	7- 14	0 - 14
		-1	0	7	14			
1	9486	225	236	245	273	9	28	37
2	9487	215	198	238	248	40	10	50
3	9488	227	210	238	264	28	26	54
4	9489	229	211	245	255	34	10	44
5	9490	235	219	247	265	28	18	46
Mean:		226.2	214.8	242.6	261.0	27.8	18.4	46.2
Standard deviation:		7.3	14.0	4.3	9.7	11.6	8.5	6.4

Standard footnotes: # = Found dead M = Moribund

Note: Day -1 prior to fasting, Day 0 prior to administration

TABLE 3 Macroscopic Findings

DOSE LEVEL: 2000 mg/kg bw, Treatment on Day 0

SEX: FEMALE

Cage No.	Animal Number	Necropsy Day	External Observations	Internal Observations	Organ/Tissue
1	9486	Day 14	No external observations recorded	No internal observations recorded	Not applicable
2	9487	Day 14	No external observations recorded	No internal observations recorded	Not applicable
3	9488	Day 14	No external observations recorded	No internal observations recorded	Not applicable
4	9489	Day 14	No external observations recorded	No internal observations recorded	Not applicable
5	9490	Day 14	No external observations recorded	No internal observations recorded	Not applicable

Standard footnotes: # = Found dead M = Moribund - = No data

APPENDICES SECTION

APPENDIX 1 AOT 425 Report (Limit Test)

ACT425statpgm (Version: 1.0) Test Results and Recommendations
Acute Oral Toxicity (OECD Test Guideline 425) Statistical Program

Date/Time: 2021. júníus 7., hétfó, 12:56:35
Data file name: work.dat
Last modified: 2021. 06. 07. 12:56:34

Test/Substance: 21/032-001P
Test type: Limit Test
Limit dose (mg/kg): 2000
Assumed LD50 (mg/kg): Default
Assumed sigma (mg/kg): 0.5

DATA:

Test Seq.	Animal ID	Dose (mg/kg)	Short-term Result	Long-term Result
1	9486	2000	O	O
2	9487	2000	O	O
3	9488	2000	O	O
4	9489	2000	O	O
5	9490	2000	O	O

{X = Died, O = Survived}

Dose Recommendation: The limit test is complete.

SUMMARY OF LONG-TERM RESULTS:

Dose	O	X	Total
2000	5	0	5
All Doses	5	0	5

Statistical Estimates:

The LD50 is greater than 2000 mg/kg.



ALS Laboratórios LS Ltda.
Rua Fábria, 59 – CEP: 05051-030
São Paulo, SP - Brazil

SYNGENTA PROTEÇÃO DE CULTIVOS Ltda.
Rua Doutor Rubens Gomes Bueno nº 891,
11º andar, Torre Sigma
CEP 04730-000 – Bairro Várzea de Baixo
São Paulo-SP – Brazil

Certificate of Analysis

A23479A
S-Metolachlor/Sulfentrazone EC (847/088)
RAN001-086-038

Batch Identification	RAN001-086-038
Product Code	A23479A
Other Product Code(s)	A23479
EUP number:	1382/ 2020 Expiry date: 21/07/2023
Received on:	06 August 2020
Source	Syngenta Proteção de Cultivos Ltda, Rodovia Professor Zeferino Vaz, SP 332, s/nº, km 127,5 – Bairro Santa Terezinha, CEP 13148-915 – Paulínia-SP – Brazil.
Chemical Analysis (Active Ingredients Content)	
– Content of S-Metolachlor *	75.30 % w/w corresponding to 848.13 g/L
– Content of Sulfentrazone *	7.71 % w/w corresponding to 86.87 g/L

The Active Ingredients contents are within the FAO limits.
Methodology used for Characterization: HPLC (SF- 1092/1)

Physical Analysis

– Density *	1.1264 g/cm ³
Stability:	
– Storage Temperature	<30°C
– Recertification Date	01 May 2022

If stored under the conditions given above, this test item can be considered stable until the recertification date is reached.

This Certificate of Analysis summarizes data which originates either from a single study or from several individual studies. Tests marked with an asterisk (*) have been conducted in compliance with GLP. All original raw data, including any storage medium for electronically recorded data, documentation, the signed study plan, the protocol amendments, the final report and a sample of the test item will be retained in the GLP Archives at ALS Laboratórios LS Ltda.

Study number of batch characterization: 23535/2020CC

Authorization: 16 October 2020

Victor F. G. da Silva
Victor Ferreira Gomes da Silva
ALS Laboratórios LS Ltda.

APPENDIX 3 Structured Study Summary

Structured Study Summary Table

Test substance design codes	S-metolachlor/sulfentrazone EC (A23479A)
Test substance batch code	RAN001-086-038
Active ingredient content*	Content of S-metolachlor: 75.30 % w/w corresponding to 848.13g/L content of sulfentrazone: 7.71 % w/w corresponding to 86.87 g/L
Density	1.1264 g/cm ³
Study number	21/032-001P
Study type	MAMMALIAN ACUTE ORAL
Lab Reference	Charles River Laboratories Hungary Kft.
Study guidelines	OECD 425 (2008), OPPTS 870.1100 (2002)
Nonstandard elements	
Species	Rat
Strain	CrI:WI Wistar
TK data collected?	No
Dose units	mg/kg bw
Substance vehicle	-
Dosing approach	undiluted
LD₅₀ - Male	-
LD₅₀ - Female	>2000 mg/kg bw

**Note: No adjustment for active ingredient content was applied.*

Structured Study Results Table

Gender	Dose (mg/kg bw)	Number of animals dosed	Number of animals survived	Clinical Observations
Female	2000	5	5	Slightly decreased activity, hunched back

APPENDIX 4 GLP Certificate



Hatósági Ellenőrzési Főosztály

1051 Budapest, Zrínyi utca 3.
Levélcímr: 1372 Postafók 450
Tel.: +36 1 886 9300, Fax: +36 1 886 9460
E-mail: ogyei@ogyei.gov.hu
Web: www.ogyei.gov.hu

Ref. no: OGYÉI/-29520-2/2021

Admin.: Dr. Szaller Zoltán

GOOD LABORATORY PRACTICE (GLP) CERTIFICATE

It is hereby certified that the test facility

Charles River Laboratories Hungary Kft.

H-8200 Veszprém, Szabadságpuszta

is able to carry out

physico-chemical testing, toxicity studies, mutagenicity studies, environmental toxicity studies on aquatic or terrestrial organisms, studies on behaviour in water, soil and air; bio-accumulation, analytical and clinical chemistry, pathology studies, preparation of microscopic tissue sections, reproduction toxicology, in vitro studies, inhalation toxicology, and contract archiving

in compliance with the Principles of GLP (Good Laboratory Practice) and also complies with the corresponding OECD/European Community requirements.

Date of the inspection: 07-11 May 2018.

This certificate is valid up to 11th of May, 2022.

Dr. Lukács
Ferenc
József

Digitálisan aláírta:
Dr. Lukács Ferenc
József
Dátum: 2021.05.06
13:04:14 +02'00'

Dr. Ferenc Lukács
Head of Inspectorate

Note: Translation of the text of the certificate in the header: ("Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézet") - ("National Institute of Pharmacy and Nutrition"); ("Hatósági Ellenőrzési Főosztály") - (Inspectorate Division) and at the signature: ("Digitálisan aláírta") - (Digitally signed); ("Dátum") - ("Date").